A Phase 3 interventional study of Vimseltinib and Placebo in Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis and Giant Cell Tumor of Tendon Sheath, sponsored by Deciphera Pharmaceuticals, LLC. Active, not recruiting at 35 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by Deciphera Pharmaceuticals, LLC (part of Ono Pharmaceutical Co. Ltd) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Synovitis, Pigmented Villonodular with a site in United States — none open to participants now, 4 under way, 3 of them phase 3. Synovitis, Pigmented Villonodular · United States.
Among the 13 studies in Synovitis, Pigmented Villonodular with a site in United States, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2021, is one of 4 in phase 3, and was the 10th registered.
20 studies on the registry are indexed under Synovitis, Pigmented Villonodular; 2 are open to participants now.
Browse Synovitis, Pigmented Villonodular studies →None of the 13 studies in Synovitis, Pigmented Villonodular with a site in United States is open now. The open studies under Synovitis, Pigmented Villonodular, anywhere →
Of the 1 Synovitis, Pigmented Villonodular study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 4
First in 2010; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 123 is above the median of 36 across 17 interventional studies indexed under Synovitis, Pigmented Villonodular.
Median enrollment 51 across the 12 interventional studies, 183 across the 1 observational. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 13 have an industry lead sponsor. The 9 most frequent:
This study is registered under Deciphera Pharmaceuticals, LLC, one of the names counted as Ono Pharmaceutical Co. Ltd. Under that name alone:
Deciphera Pharmaceuticals, LLC is the lead sponsor of 24 studies on the registry; 5 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.
Ono Pharmaceutical Co. Ltd has 2 studies filed under Synovitis, Pigmented Villonodular — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Synovitis, Pigmented Villonodular with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT) in cases where surgical removal of the tumor is not an option.
The study consists of two parts. In Part 1, eligible study participants will be assigned to receive either vimseltinib or matching placebo for 24 weeks. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. MRI scans will be used to evaluate the response of the tumors to the treatment. Participants assigned to placebo in Part 1 will have the option to receive vimseltinib for Part 2. Part 2 is a long-term treatment phase in which all participants receive open-label vimseltinib.
20 studies on the registry are indexed under Synovitis, Pigmented Villonodular; 2 are open to participants now.
This study's enrollment of 123 is above the median of 36 across 17 interventional studies indexed under Synovitis, Pigmented Villonodular.
Browse Synovitis, Pigmented Villonodular studies →Deciphera Pharmaceuticals, LLC is the lead sponsor of 24 studies on the registry; 5 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.
First submitted before Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd.
Compared within Synovitis, Pigmented Villonodular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Giant Cell Tumor of Tendon Sheath. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received blinded treatment of 30 mg twice a week (BIW) vimseltinib for 24 weeks in Part 1 and open-label 30 mg BIW vimseltinib in Part 2.
Drug: Vimseltinib
Participants received blinded treatment of BIW matching placebo for 24 weeks in Part 1 and open-label 30 mg BIW vimseltinib in Part 2.
Drug: Vimseltinib · Drug: Placebo
Administered orally
Also known as: DCC-3014
Administered orally
Objective Response Rate (ORR) at Week 25 Per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1
ORR was assessed by blinded independent radiologic review (IRR) using RECIST Version 1.1. ORR was defined as the percentage of participants who achieved either complete response (CR) or partial response (PR). * CR: Disappearance of all target lesions. Any pathological lymph nodes must be \<10 millimeter (mm) in short axis. Non-nodal targets must be absent. * PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Baseline to Week 25 (Cycle 7, Day 1)
ORR at Week 25 Per Tumor Volume Score (TVS)
TVS is a semi-quantitative magnetic resonance imaging (MRI) scoring system that describes tumor mass and is based on 10% increments of the estimated volume of the maximally distended synovial cavity or tendon sheath involved. A tumor that is equal in volume to that of a maximally distended synovial cavity or tendon sheath was scored 10; a score of 0 indicated no evidence of tumor. ORR was the percentage of participants who achieved either CR or PR as assessed by blinded IRR using TVS. * CR: Lesion completely gone * PR: ≥50% decrease in volume score relative to Baseline.
Time frame: Baseline to Week 25 (Cycle 7, Day 1)
Change From Baseline in Active Range of Motion (ROM) at Week 25
Presented here is the change from baseline in active ROM to Week 25. Measurement of the affected and contralateral, non-affected joint was assessed by goniometer and measured in degrees. At baseline, the motion with the smallest relative ROM value (worst) was identified, and this motion was used for evaluating the change in relative ROM subsequently. The affected joint measurement was used to derive a relative ROM based on active measurement relative to reference standard value provided by the American Medical Association. Relative ROM is expressed in percent: 100 x (joint ROM measure)/(reference ROM standard).
Time frame: Baseline to Week 25 (Cycle 7, Day 1)
Change From Baseline in the Patient-reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Score at Week 25
All participants were asked 15 questions from the PROMIS-PF item bank. The questions used one of two 5-point verbal rating scales: either 1 = "unable to do", 2 = "with much difficulty", 3 = "with some difficulty", 4 = "with a little difficulty", and 5 = "without any difficulty"; or 1 = "cannot do", 2 = "quite a lot", 3 = "somewhat", 4 = "very little", and 5 = "not at all." Total scores were converted to T-scores that ranged from 0 to 100, with higher scores representing less physical function interference and better health outcomes.
Time frame: Baseline to Week 25 (Cycle 7, Day 1)
Change From Baseline in the Worst Stiffness Numeric Rating Scale (NRS) Score at Week 25
The Worst Stiffness NRS is a single question that asks the participant to assess their worst stiffness in the last 24 hours. Participants rate their worst stiffness on a scale of 0 to 10, where 0 is "no stiffness" and 10 is "worst imaginable." Lower scores represented better level of stiffness.
Time frame: Baseline to Week 25 (Cycle 7, Day 1)
Change From Baseline in EuroQoL Visual Analogue Scale (EQ-VAS) at Week 25
The EQ-VAS is a standardized tool for measuring overall health. EQ-VAS recorded the participant's self-rated health on a vertical VAS scale ranging from a minimum of 0 (worst imaginable health state) to a maximum of 100 (best imaginable health state). Higher scores indicated better health state.
Time frame: Baseline to Week 25 (Cycle 7, Day 1)
Percentage of Participants With Response at Week 25 Based on Brief Pain Inventory (BPI) Worst Pain NRS Score and Narcotic Analgesic Use
Participants reported responses to the BPI Worst Pain NRS. The BPI Worst Pain NRS ranged from 0 to 10, where 0 is "no pain" and 10 is "pain as bad as you can imagine." A responder was defined as a participant who: (i) experienced a decrease of at least 30% in the mean BPI Worst Pain NRS item and (ii) did not experience a 30% or greater increase in narcotic analgesic use.
Time frame: Baseline to Week 25 (Cycle 7, Day 1)
| Milestone | Part 1/Part 2: Vimseltinib/Vimseltinib | Part 1/Part 2: Placebo/Vimseltinib |
|---|---|---|
| Started | 83 | 40 |
| Received at least 1 dose of study drug | 83 | 39 |
| Completed | 75 | 35 |
| Not completed | 8 | 5 |
| Withdrew: Subsequent tgct therapy and/or surgery | 3 | 0 |
| Withdrew: Withdrawal by subject | 3 | 3 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Other reasons | 0 | 1 |
| Withdrew: Ongoing in study | 1 | 0 |
| Milestone | Part 1/Part 2: Vimseltinib/Vimseltinib | Part 1/Part 2: Placebo/Vimseltinib |
|---|---|---|
| Started | 74 | 35 |
| Received at least 1 dose of study drug | 72 | 35 |
| Completed | 0 | 0 |
| Not completed | 74 | 35 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Ongoing in study | 73 | 32 |
ORR was assessed by blinded independent radiologic review (IRR) using RECIST Version 1.1. ORR was defined as the percentage of participants who achieved either complete response (CR) or partial response (PR). * CR: Disappearance of all target lesions. Any pathological lymph nodes must be \<10 millimeter (mm) in short axis. Non-nodal targets must be absent. * PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants with CR or PR | Vimseltinib | Placebo |
|---|---|---|
| Objective Response Rate (ORR) at Week 25 Per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 | 39.8 (29.2 to 51.1) | 0 (0.0 to 8.8) |
TVS is a semi-quantitative magnetic resonance imaging (MRI) scoring system that describes tumor mass and is based on 10% increments of the estimated volume of the maximally distended synovial cavity or tendon sheath involved. A tumor that is equal in volume to that of a maximally distended synovial cavity or tendon sheath was scored 10; a score of 0 indicated no evidence of tumor. ORR was the percentage of participants who achieved either CR or PR as assessed by blinded IRR using TVS. * CR: Lesion completely gone * PR: ≥50% decrease in volume score relative to Baseline.
| percentage of participants | Vimseltinib | Placebo |
|---|---|---|
| ORR at Week 25 Per Tumor Volume Score (TVS) | 67.5 (56.3 to 77.4) | 0 (0.0 to 8.8) |
Presented here is the change from baseline in active ROM to Week 25. Measurement of the affected and contralateral, non-affected joint was assessed by goniometer and measured in degrees. At baseline, the motion with the smallest relative ROM value (worst) was identified, and this motion was used for evaluating the change in relative ROM subsequently. The affected joint measurement was used to derive a relative ROM based on active measurement relative to reference standard value provided by the American Medical Association. Relative ROM is expressed in percent: 100 x (joint ROM measure)/(reference ROM standard).
| Change in percent | Vimseltinib | Placebo |
|---|---|---|
| Change From Baseline in Active Range of Motion (ROM) at Week 25 | 18.4 ± 6.46 | 3.8 ± 7.19 |
All participants were asked 15 questions from the PROMIS-PF item bank. The questions used one of two 5-point verbal rating scales: either 1 = "unable to do", 2 = "with much difficulty", 3 = "with some difficulty", 4 = "with a little difficulty", and 5 = "without any difficulty"; or 1 = "cannot do", 2 = "quite a lot", 3 = "somewhat", 4 = "very little", and 5 = "not at all." Total scores were converted to T-scores that ranged from 0 to 100, with higher scores representing less physical function interference and better health outcomes.
| score on a scale | Vimseltinib | Placebo |
|---|---|---|
| Change From Baseline in the Patient-reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Score at Week 25 | 4.6 ± 0.96 | 1.3 ± 0.88 |
The Worst Stiffness NRS is a single question that asks the participant to assess their worst stiffness in the last 24 hours. Participants rate their worst stiffness on a scale of 0 to 10, where 0 is "no stiffness" and 10 is "worst imaginable." Lower scores represented better level of stiffness.
| score on a scale | Vimseltinib | Placebo |
|---|---|---|
| Change From Baseline in the Worst Stiffness Numeric Rating Scale (NRS) Score at Week 25 | -2.1 ± 0.24 | -0.3 ± 0.28 |
The EQ-VAS is a standardized tool for measuring overall health. EQ-VAS recorded the participant's self-rated health on a vertical VAS scale ranging from a minimum of 0 (worst imaginable health state) to a maximum of 100 (best imaginable health state). Higher scores indicated better health state.
| score on a scale | Vimseltinib | Placebo |
|---|---|---|
| Change From Baseline in EuroQoL Visual Analogue Scale (EQ-VAS) at Week 25 | 13.5 ± 2.35 | 6.1 ± 2.85 |
Participants reported responses to the BPI Worst Pain NRS. The BPI Worst Pain NRS ranged from 0 to 10, where 0 is "no pain" and 10 is "pain as bad as you can imagine." A responder was defined as a participant who: (i) experienced a decrease of at least 30% in the mean BPI Worst Pain NRS item and (ii) did not experience a 30% or greater increase in narcotic analgesic use.
| percentage of participants | Vimseltinib | Placebo |
|---|---|---|
| Percentage of Participants With Response at Week 25 Based on Brief Pain Inventory (BPI) Worst Pain NRS Score and Narcotic Analgesic Use | 48.2 (37.1 to 59.4) | 22.5 (10.8 to 38.5) |
Collected over Collection of adverse events started from the signing of informed consent through safety follow-up (up to 1.68 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Total - Vimseltinib | 1/118 (0.8%) | 17/118 (14.4%) | 113/118 (95.8%) |
| Placebo | 0/39 (0%) | 1/39 (2.6%) | 32/39 (82.1%) |
| Event | Total - Vimseltinib | Placebo |
|---|---|---|
| CellulitisInfections and infestations | 4/118 | 0/39 |
| DiarrhoeaGastrointestinal disorders | 0/118 | 1/39 |
| VomitingGastrointestinal disorders | 0/118 | 1/39 |
| FallInjury, poisoning and procedural complications | 2/118 | 0/39 |
| Myocardial ischaemiaCardiac disorders | 1/118 | 0/39 |
| UveitisEye disorders | 1/118 | 0/39 |
| Inguinal herniaGastrointestinal disorders | 1/118 | 0/39 |
| Localised infectionInfections and infestations | 1/118 | 0/39 |
| ParonychiaInfections and infestations | 1/118 | 0/39 |
| Rhinovirus infectionInfections and infestations | 1/118 | 0/39 |
| Event | Total - Vimseltinib | Placebo |
|---|---|---|
| Periorbital oedemaEye disorders | 53/118 | 5/39 |
| Face oedemaGeneral disorders | 34/118 | 3/39 |
| PruritusSkin and subcutaneous tissue disorders | 33/118 | 3/39 |
| FatigueGeneral disorders | 31/118 | 6/39 |
| HeadacheNervous system disorders | 30/118 | 10/39 |
| AstheniaGeneral disorders | 30/118 | 9/39 |
| Aspartate aminotransferase increasedInvestigations | 30/118 | 1/39 |
| NauseaGastrointestinal disorders | 26/118 | 8/39 |
| Blood creatine phosphokinase increasedInvestigations | 26/118 | 0/39 |
| RashSkin and subcutaneous tissue disorders | 25/118 | 2/39 |
The Intent-to-Treat (ITT) Set consisted of participants who were randomized to a study treatment regimen. Presented here are data from Part 1 baseline period.
| Age, Continuous(years) | Part 1/Part 2: Vimseltinib/Vimseltinib | Part 1/Part 2: Placebo/Vimseltinib | Total |
|---|---|---|---|
| Mean | 43.8 ± 13.92 | 42.5 ± 13.67 | 43.4 ± 13.80 |
| Sex: Female, Male(Participants) | Part 1/Part 2: Vimseltinib/Vimseltinib | Part 1/Part 2: Placebo/Vimseltinib | Total |
|---|---|---|---|
| Female | 46 | 27 | 73 |
| Male | 37 | 13 | 50 |
| Ethnicity (NIH/OMB)(Participants) | Part 1/Part 2: Vimseltinib/Vimseltinib | Part 1/Part 2: Placebo/Vimseltinib | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 4 |
| Not Hispanic or Latino | 62 | 23 | 85 |
| Unknown or Not Reported | 18 | 16 | 34 |
| Race (NIH/OMB)(Participants) | Part 1/Part 2: Vimseltinib/Vimseltinib | Part 1/Part 2: Placebo/Vimseltinib | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 4 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 0 | 4 |
| White | 59 | 21 | 80 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 19 | 15 | 34 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2021 to primary completion in Aug 2023, 21 months.
Results were first posted in Feb 2025, 1 year 6 months after primary completion. A results delay was requested in Aug 2024.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vimseltinib
Synovitis, Pigmented Villonodular →
Deciphera Pharmaceuticals, LLC →